PNC-27
Membranolytic peptide that selectively kills cancer cells expressing HDM-2 (oncoprotein) on the membrane surface. Pre-clinical anti-cancer research compound.
PNC-27: Membranolytic peptide that selectively kills cancer cells expressing HDM-2 (oncoprotein) on the membrane surface. Pre-clinical anti-cancer research compound. PNC-27 is a peptide that punches holes in cancer-cell membranes by binding HDM-2, an oncoprotein found on tumor cell surfaces.
PNC-27 is a peptide that punches holes in cancer-cell membranes by binding HDM-2, an oncoprotein found on tumor cell surfaces. Healthy cells don't express HDM-2 on the surface, so it's selective in theory. Pre-clinical research compound, not approved for treatment.
Not prescribed in conventional medicine outside research contexts.
Who it's for
- →Cancer-research contexts under medical oversight
- →Educational reference, pre-clinical only
- →Compassionate-use research scenarios
What to expect
- Week 1
Acute responses in animal/cell models.
- Week 4
Pre-clinical endpoint.
- Week 8
No human long term safety data.
Looking at PNC-27? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for PNC-27.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Membranolytic peptide. Selectively binds HDM-2 (an oncoprotein) found on the membrane surface of cancer cells (rarely on healthy cells), then lyses the cell membrane. Pre-clinical anti-cancer mechanism.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Anyone without medical oversight
- ⚠Pregnancy / nursing
- ⚠Active autoimmune conditions
Bloodwork to monitor
- • CBC, CMP, LFTs at minimum if researching
Common mistakes
- • Self-administering for cancer treatment (this is pre-clinical, not approved)
- • Skipping medical oversight
- • Long cycles without safety monitoring
What it actually is
PNC-27 is a laboratory-designed peptide that joins a fragment of the p53 tumour suppressor protein to a cell-penetrating sequence. In cell culture it kills cancer cells while leaving normal cells intact. It is a preclinical anti-cancer research compound with zero human trials, and it is sold to people with cancer, which makes it the most ethically fraught entry in this catalog.
Some cancer cells display HDM-2, a protein that normally sits inside the cell suppressing p53, on their outer membrane instead. In the published cell-line work the normal cells tested did not, which is the basis for the selectivity claim — it is an observation in specific cell lines rather than an established property of all healthy tissue. PNC-27's p53-derived segment binds that membrane HDM-2, and the attached penetrating sequence then forms pores in the membrane, causing the cell to rupture — necrosis rather than programmed cell death. The proposed selectivity rests on healthy cells not displaying the target, which has been observed in the cell lines tested rather than established across human tissue. That is a genuinely elegant idea and it has never been tested in a person.
Forms, and which is which
All published work is in cell lines and animal models. No standardised human dose exists.
Verdict: The honest description of what this is.
Marketed to people with cancer diagnoses. No human dosing basis exists, identity cannot be verified, and no efficacy or safety data exists at any dose.
Verdict: Sold into the most vulnerable possible situation, with nothing behind it.
These have been through real clinical trials with real toxicity findings, and none is FDA-approved — the class remains investigational. They also work differently, blocking the MDM2-p53 interaction inside the cell rather than forming pores at the membrane.
Verdict: The same target taken through actual trials, and still not approved.
Combines an untested compound with others, in a population where a wrong decision costs the most.
Verdict: Compounding an already unacceptable risk.
What it is claimed to do, graded
Demonstrated repeatedly in cell lines, including leukaemia cells while sparing normal bone marrow cells. This is real laboratory work published in reputable journals.
Structurally characterised, including in a 2010 PNAS paper. The mechanism is well described.
Zero human trials, zero randomised trials. Cell-line selectivity has failed to translate for a very long list of compounds before this one.
No human safety data at any dose. A membrane-disrupting peptide has obvious potential for off-target harm and nobody has measured it.
Stating this plainly because the stakes are highest here: there is no evidence for this, and delaying treatment that does work is how an unproven compound causes the most harm.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • The mechanism is genuinely novel and well characterised in the laboratory
- • Published in reputable peer-reviewed journals including PNAS
- • The selectivity principle, targeting a protein displayed only on cancer cell membranes, is sound in vitro
- • Zero human trials of any kind
- • Sold to people with cancer diagnoses, which is where an unproven compound does the most damage
- • No standardised human dose exists, so any protocol offered was invented
- • Membrane-disrupting peptides have obvious off-target potential that nobody has characterised in people
- • The greatest risk is not the compound itself but what taking it might replace or delay
When to stop
- • Before starting, and instead have the conversation with your oncologist — that is the honest answer for this compound
- • Any new or unexplained symptom
- • Any sign that it is being used in place of a treatment with evidence behind it
Interactions
Nothing is known about how this interacts with chemotherapy, radiotherapy or immunotherapy. Any decision here belongs to an oncologist with the full picture.
The single most important line on this page. There is no evidence base to justify it.
Cell lysis releases cellular contents, which is an immune stimulus. Unstudied.
Membrane-active peptides and clotting have no interaction data here.
There is no human interaction literature for this compound at all.
Is this for you?
- • Laboratory research. There is no human context for this compound, and the population it is marketed to is the one with the most to lose from an unproven choice
- • You have a cancer diagnosis and are considering this instead of, or alongside, treatment — talk to your oncologist first
- • You are pregnant or nursing
- • You have an autoimmune condition
- • You want anything resembling human evidence
The one number
Sources for the claims above
- Adopts an HDM-2-binding conformation and kills cancer cells
- Induces necrosis in leukaemia cells but not normal cells
- Structural characterisation of HDM-2 binding
New to PNC-27? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about PNC-27 or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is PNC-27?+
Is PNC-27 FDA approved?+
Is PNC-27 legal?+
Is PNC-27 banned by WADA?+
Are you still natty after taking PNC-27?+
Do doctors prescribe PNC-27?+
What's the typical dose of PNC-27?+
What are the side effects of PNC-27?+
How long until PNC-27 starts working?+
What can you stack with PNC-27?+
Where do people get PNC-27?+
Common questions about PNC-27
Tracked alongside PNC-27
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Immune
Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.
A germ-fighter your immune system already makes on its own. It's a cathelicidin-derived antimicrobial peptide used for chronic infections and biofilm-associated issues.
Endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker.
Calms inflammation in the gut and skin. A tripeptide fragment of alpha-MSH used for gut conditions and skin inflammation.